Home › Research › Risk factors
Atypical Antipsychotics in Late-Life and Treatment-Resistant Depression
Trista Askins Bailey, Sehrish Panjwani. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2018-02-01
Topic: Drug trials: efficacy and safety
As persons age, their risk of developing late-life depression increases. Older adults not only have an increased risk of late-life depression, but they also have an increased risk of suicidal ideation. Because of these increased risks, it is vital that clinicians be aware of the options available to assist these persons to achieve remission of their symptoms, as well as prevent relapse. Atypical antipsychotics have been considered an augmentation option in younger adults with depression. However, because of the black box warning associated with atypical antipsychotics in older adults with dementia, clinicians often exercise caution when using these agents to help treat late-life depression. This article explores the various studies conducted for the use of atypical antipsychotics in older adults and their safety and efficacy in this population.
Key findings
- Older adults not only have an increased risk of late-life depression, but they also have an increased risk of suicidal ideation.
- However, because of the black box warning associated with atypical antipsychotics in older adults with dementia, clinicians often exercise caution when using these agents to help treat late-life depression.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Evidence strengthLow
How this study scored 39/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 22 of the 56 points we could judge it on, which is 39 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 29409574) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 22 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 22 of the 56 points we could judge it on is 39 out of 100. |
| Total | 39 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Bailey, T. A., & Panjwani, S. (2018). Atypical Antipsychotics in Late-Life and Treatment-Resistant Depression. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists. https://doi.org/10.4140/tcp.n.2018.83
Vancouver
Bailey TA, Panjwani S. Atypical Antipsychotics in Late-Life and Treatment-Resistant Depression. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists. 2018. doi:10.4140/tcp.n.2018.83. PMID: 29409574.
BibTeX
@article{bailey2018-29409574,
author = {Bailey, Trista Askins and Panjwani, Sehrish},
title = {{Atypical Antipsychotics in Late-Life and Treatment-Resistant Depression}},
journal = {The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists},
year = {2018},
doi = {10.4140/tcp.n.2018.83},
pmid = {29409574},
url = {https://doi.org/10.4140/tcp.n.2018.83}
}
Related studies in Risk factors
Also tagged “late-life-depression”
139 studies in the library carry the topic tag “late-life-depression”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 139 tagged studies.